Earlier today, Israel-based cannabinoid biotech company, Intec Pharma Ltd. (TASE:NTEC)(NASDAQ:NTEC) announced that the company has been granted a patent in Hong Kong for an accordion pill (the company's proprietary drug delivery technology) containing certain drugs including the combination of Carbidopa and Levodopa (one of Intec's non-cannabinoid products in developments). The patent is currently scheduled to remain in force until April 2029.
Now Read: Inside Intec Pharma's Accordion Pill Technology
Intec Pharma's CEO, Jeffrey A. Meckler
"We remain committed to building out our IN-7 patent family in order to fortify our global leadership in gastric retention drug delivery with the Accordion Pill technology platform and this patent further strengthens that position. This Hong Kong patent secures key elements of our Accordion Pill technology platform and our leading product, the Accordion Pill Carbidopa/Levodopa (AP-CD/LD), in significant markets. The AP-CD/LD is currently in a global Phase III clinical trial in advanced Parkinson's disease and the expanded patent protection will enhance any global commercial efforts for AP-CDLD."
Shares of Intec Pharma trading on the Tel Aviv Stock Exchange closed today's session (prior to the news release) higher by 0.26% on the day. In midday North American trading, shares of Intec on the NASDAQ are rising more than 1.5% on light trading volume. Year-to-date, Intec shares on the Tel Aviv Stock Exchange are down roughly 4%.
Now Read: Tel Aviv Listed Marijuana Stocks
For more information on Intec Pharma Ltd., be sure to check out the company's profile in our global marijuana stock database. Remember, the NASDAQ-listed shares of Intec can be traded commission free using the Robinhood app.
Subscribe to one or more of our free e-mail newsletters (including our cannabinoid biotech and pharma newsletter) so you never miss an important cannabis stock update.
Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram.
Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.